PROKIDNEY CORP.·4

May 29, 4:06 PM ET

Fox Jennifer A. 4

Research Summary

AI-generated summary

Updated

PROK Director Jennifer Fox Receives 135,000 Option Award

What Happened

  • Jennifer A. Fox, a director of ProKidney Corp. (PROK), was granted 135,000 derivative securities (reported as acquired at $0.00) on 2026-05-28. This was an award of options/rights under the issuer's non-employee director compensation policy — no cash purchase was reported.

Key Details

  • Transaction date: 2026-05-28; Form 4 filed: 2026-05-29 (timely).
  • Quantity: 135,000 options/awarded derivative securities; acquisition price reported as $0.00 (award/grant).
  • Shares owned after transaction: Not specified in the provided filing excerpt.
  • Footnotes: (1) Granted under the issuer’s non-employee director compensation policy. (2) Vesting: the options vest in full on the earlier of the one‑year anniversary of the grant or the Company’s next annual shareholder meeting.
  • Filing timeliness: Filed the day after the grant (no late filing flag in the information provided).

Context

  • This is a compensation grant to a non-employee director, not an open‑market purchase or sale. Such grants are common for board compensation and reflect future potential equity rather than an immediate cash investment or sale. The award will convert to exercisable/vested rights per the stated vesting schedule; strike price or other exercise terms were not detailed in the provided summary.